There are currently 578 clinical trials in Louisville, Kentucky looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Louisville, Jewish Hospital, Norton Cancer Institute and Norton Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Interventional Study Exploring the Occurrence of Surgical Site Infections.
NCT06661473
Recruiting
Interventional study exploring surgical site complication occurrences in high-risk revision patients undergoing TKA or THA using NPWT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2024
Locations: University of Louisville, Louisville, Kentucky
Conditions: Total Knee Arthroplasty, Total Hip Arthroplasty Revision, Total Knee Arthroplasty Revision
Register for Updates
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML
NCT05735184
Recruiting
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: Norton Cancer Institute - St. Matthews, Louisville, Kentucky
Conditions: Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
Register for Updates
Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy
NCT06145035
Recruiting
This is a Phase IIA, randomized, double blind, placebo controlled, multicenter study designed to assess the safety, feasibility, and efficacy of umbilical cord derived mesenchymal stromal cells (UC MSCs), administered intravenously (IV) as a single dose or repeated doses, in patients with ischemic cardiomyopathy (ICM).
Gender:
ALL
Ages:
Between 21 years and 85 years
Trial Updated:
10/23/2024
Locations: University of Louisville School of Medicine, Institute of Molecular Cardiology, Louisville, Kentucky
Conditions: Ischemic Heart Disease
Register for Updates
Administration of Allogeneic-MSC in Patients with Non-Ischemic Dilated Cardiomyopathy
NCT04476901
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/21/2024
Locations: University of Louisville, Louisville, Kentucky
Conditions: Non-ischemic Dilated Cardiomyopathy
Register for Updates
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
NCT05863351
Recruiting
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where it first started (primary site) to a limited (2-5) number of places in the body (metastatic). Study doctors want to find out if this approach is better or worse than the usual approach for metastatic kidney cancer. The usual approach is defined as the care most people get... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky
Conditions: Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Register for Updates
Harm Reduction for Smokers With Mental Illness
NCT06543407
Recruiting
To compare the efficacy of e-cigarette (e-cig) provision with or without behavioral support (SWITCH IT) delivered via telehealth to reduce harm among smokers with MI who cannot quit smoking and are not ready to pursue cessation treatment, and to examine self-regulation (using e-cigs instead of cigarettes to cope with stress/distress and self-efficacy) as a potential mechanism for behavior change from SWITCH IT
Gender:
ALL
Ages:
21 years and above
Trial Updated:
10/15/2024
Locations: Seven Counties Services, Louisville, Kentucky
Conditions: Tobacco Dependence
Register for Updates
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835
Recruiting
This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same. Z... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/12/2024
Locations: Norton Heart Specialists-Springs, Louisville, Kentucky
Conditions: Cardiovascular Risk, Chronic Kidney Disease, Inflammation
Register for Updates
Complex and Simple Appendicitis: REstrictive or Liberal Post-operative Antibiotic eXposure (CASA RELAX)
NCT05838248
Recruiting
This prospective trial will randomize patients who have had an appendectomy to two different durations of antibiotic therapy depending on the status of the appendicitis. For simple appendicitis, patients will be randomized to peri-operative antibiotics or 24 hours duration. For complex appendicitis, patients will be randomized to 24 hours or 4 days duration. Data will be collected prospectively and test the hypothesis that shorter durations of antibiotics will be non-inferior to the longer durat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: Jewish Hospital UL, Louisville, Kentucky +1 locations
Conditions: Appendicitis
Register for Updates
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864
Recruiting
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
10/02/2024
Locations: Research Site, Louisville, Kentucky
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Register for Updates
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
NCT06129240
Recruiting
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/01/2024
Locations: Norton Pulmonary Specialists, Louisville, Kentucky
Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
Encouraging a Plant Based Diet in an Underserved Urban Population
NCT06090409
Recruiting
The investigator's goal is to promote a plant-based diet amongst the underserved urban population of Louisville with the help of educational aids and the provision of affordable resources.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2024
Locations: University of Louisville Ambulatory Internal Medicine Resident Clinic, Louisville, Kentucky
Conditions: Food Neophobia, Food Preferences, Dietary Habits
Register for Updates
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
NCT04561362
Recruiting
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency. The primary endpoints are: Dose limiting toxicities (Parts A-1 and A-2), Overall response rate per RECIST v1.1 (Parts B1-B7), Safety and tolerability (Parts B-8, B-9 and C),... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Norton Cancer Institute, Downtown, Louisville, Kentucky
Conditions: Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Ovarian Neoplasm, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms
Register for Updates